AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35795564
Drug: Oil Palm
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil Palm Phenolics (OPP) 250 mg
Trial: 33053048
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with Ringer's solution without FAW
Trial: 36423442
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus up to 26 sessions of TwV therapy
Trial: 34543267
Drug: Patient-centered integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered integrated chronic care model including treatment for hypertension, diabetes, and HIV.
Trial: 34543267
Drug: Standard country-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard country-guided treatment (control group).
Trial: 37815957
Drug: Traditional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medicine
Trial: 32884020
Drug: Fenofibrate 145
RxNorm normalized name: fenofibrate 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg per day
Trial: 36619724
Drug: HP eradication
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP eradication treatment
Trial: 36619724
Drug: Standard NASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard NASH treatment
Trial: 32567544
Drug: Combination sitagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination sitagliptin and metformin
Trial: 35468325
Drug: Tirzepatide 10
RxNorm normalized name: tirzepatide 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 10 mg and 15 mg
Trial: 32734238
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution
Trial: 35581902
Drug: Low-dose lobeglitazone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lobeglitazone (0.25 mg/day)
Trial: 35581902
Drug: Standard-dose lobeglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose lobeglitazone (0.5 mg/day)
Trial: 35089153
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioral therapy (iCBT) for 5 weeks
Trial: 38504157
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioral therapy (iCBT)
Trial: 34237697
Drug: Enhanced nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced nutritional supplement
Trial: 32120787
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of water-soluble coenzyme Q10 (Q10Vital®) and collagen
Trial: 39237149
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine
Trial: 35038165
Drug: Sham subcutaneous
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham subcutaneous injection of normal saline
Trial: 34127273
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with AChEI medications (sham-taper group)
Trial: 34127273
Drug: Treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment discontinuation via tapering (real-taper group)
Trial: 34127273
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (sham-taper and real-taper)
Trial: 37882059
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg)
Trial: 36246996
Drug: Perioperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative intravenous amiodarone infusion
Trial: 33431619
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical treatment
Trial: 38803637
Drug: Tablet
RxNorm normalized name: TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: 32320007
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive behavioral therapy
Trial: 33054695
Drug: Breakfast containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast containing 20% of the total recommended daily calories
Trial: 34293304
Drug: Semaglutide 2·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 2·0 mg
Trial: 33765335
Drug: Gemtuzumab ozogamycin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamycin (GO) 6 mg/m2 added to standard chemotherapy
Trial: 37755371
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (EOF)
Trial: 35288386
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise training (RET) combined with leucine and vitamin D-enriched whey protein-based oral nutritional supplement (2 times per day) for 13 weeks plus usual care
Trial: 35291004
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, Arm 1)
Trial: 34468869
Drug: Paclitaxel (standard-dose)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (standard-dose)
Trial: 32164762
Drug: Peficitinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (100 mg, or 50 mg for patients transferring from RAJ1), administered orally once daily
Trial: 33370847
Drug: Stabilised aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilised aqueous silver fluoride solution (AgF) with Potassium Iodide (KI)
Trial: 33493023
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of hemp protein (hemp40)
Trial: 33493023
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of hemp protein (hemp20)
Trial: 36517849
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment (MMT)
Trial: 34195577
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 mg orally twice daily, reduced to once daily if eGFR was reduced)
Trial: 35180719
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod (6.25 mg 3 times weekly for 8 to 16 weeks)
Trial: 33651671
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg, two infusions administered two weeks apart)
Trial: 32739962
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) 266 mg plus bupivacaine HCl 50 mg
Trial: 32739962
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl 50 mg alone
Trial: 33446506
Drug: 2.5-cm 22G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-cm 22G peripheral intravenous catheter (PIVC)
Trial: 35236778
Drug: Postbiotic lozenge
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postbiotic lozenge
Trial: 34587302
Drug: Tenofovir amibufenamide
RxNorm normalized name: Tenofovir amibufenamide
DrugBank: Tenofovir amibufenamide (DB18805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir amibufenamide (TMF) 25 mg
Trial: 34919250
Drug: Myo-Inositol (myo-Ins)
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-Inositol (myo-Ins) plus Oral Contraceptive Pills (OCP)
Trial: 34514929
Drug: Etanercept weekly
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept weekly (n=34)
Trial: 32617061
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid therapy
Trial: 33738704
Drug: 3% melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% melatonin oral gel
Trial: 32690074
Drug: Nasal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation with budesonide (1mg/2mL diluted in 250mL of physiological saline 9°/00) for 30 days, along with olfactory rehabilitation twice a day.
Trial: 32690074
Drug: Nasal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation with physiological saline 9°/00 only for 30 days, along with olfactory rehabilitation twice a day.
Trial: 34547450
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (MT)
Trial: 33938371
Drug: 6‐(Methylsulfinyl)hexyl isothiocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐(Methylsulfinyl)hexyl isothiocyanate (6‐MSITC) 9 mg/day
Trial: 34799113
Drug: Acetaminophen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (50 mg/kg of BW) mixed with MR
Trial: 34799113
Drug: Feeding frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feeding frequency and feeding rate treatments
Trial: 33126931
Drug: Intervention involving
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention involving in-service training provided by nurses, work process organisation, and additional clinic-specific solutions in six clinics.
Trial: 32692216
Drug: Modified Dachengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Dachengqi decoction combined with conventional therapy
Trial: 33087178
Drug: 7-session online
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-session online cognitive behavioral therapy (CBT) program
Trial: 32605909
Drug: Standard-dose pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose pembrolizumab plus reduced-dose ipilimumab
Trial: 33601921
Drug: Aspirin, Enoxaparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Enoxaparin, Warfarin
Trial: 33758499
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (90 mg ticagrelor tablets) under fed conditions
Trial: 33758499
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (90 mg ticagrelor tablets) under fasting conditions
Trial: 33758499
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (90 mg ticagrelor tablets) under fed conditions
Trial: 33826785
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid 250 mg twice daily for three months
Trial: 33826785
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid combined with topical hydroquinone 4% cream
Trial: 33826785
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid combined with two sessions of 1064 nm low-fluence Q-switched Nd:YAG laser
Trial: 32033908
Drug: Palucorcel (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palucorcel (3.0 × 10^5 cells in 50 μl) administered via subretinal injection
Trial: 32876714
Drug: Pudendal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal block with ropivacaine 7.5 mg/ml
Trial: 32251064
Drug: Generalized linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generalized linear model for the conditional mean of the mediator given treatment and baseline confounders.
Trial: 32251064
Drug: Education as
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education as a treatment variable.
Trial: 33025051
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg)
Trial: 33036701
Drug: MI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI plus ω‐3 (800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid/day)
Trial: 33546963
Drug: Cleaning routines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleaning routines with and without daily and/or weekly cleaners
Trial: 32573956
Drug: TAS-303 8-18
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-303 8-18 mg
Trial: 33030881
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol plus Foley bulb (100 micrograms)
Trial: 35211010
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at 1 μg.kg−1
Trial: 35211010
Drug: Oral dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexmedetomidine at 4 μg.kg−1
Trial: 33188392
Drug: Dietary concentration
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary concentration of ergovaline: 0, 0.862, and 1.282 mg/kg of diet (experiment 1)
Trial: 33188392
Drug: Endophyte-infected seeds
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endophyte-infected seeds providing ergovaline dosage of 15 μg/kg BW (experiment 2)
Trial: 35150143
Drug: Nano-curcumin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (160 mg for 10 days)
Trial: 36199630
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg lidocaine (L0.5)
Trial: 32572778
Drug: Citrus aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus aurantium essential oil inhalation for 15–20 min about 60 min before angiography
Trial: 32572778
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water inhalation (control group)
Trial: 32768315
Drug: High EAA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High EAA (0.3 g/kg, 23.5 ± 2.54 g)
Trial: 32768315
Drug: Standard EAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard EAA (0.1 g/kg, 7.87 ± 0.87 g)
Trial: 32241789
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment
Trial: 35917753
Drug: Waitlist with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist with treatment advice (WL/TA)
Trial: 33610906
Drug: Compassionate Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassionate Focused Therapy (CFT)
Trial: 35428718
Drug: MTX+ETN combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX+ETN combination therapy
Trial: 35421019
Drug: Camelina sativa
RxNorm normalized name: CAMELINA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camelina sativa oil (CSO) supplement for 12 weeks
Trial: 33074284
Drug: Rivaroxaban, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban, 15 mg daily
Trial: 35178708
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual alone
Trial: 32065623
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg zilucoplan SC daily
Trial: 32065623
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg zilucoplan
Trial: 32065623
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg zilucoplan
Trial: 39730078
Drug: digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digital cognitive behavioral therapy for insomnia (dCBT-I)
Trial: 35788070
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (daily tablet for 6 months)
Trial: 35788070
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily tablet for 6 months)
Trial: 33620905
Drug: Nitrofurantoin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (100 mg) twice-daily for 5 days
Trial: 33620905
Drug: Placebo twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo twice-daily for 5 days
Trial: 32430459
Drug: Drugs (fostamatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs (fostamatinib, zinc)
Trial: 34684525
Drug: Salmon (246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon (246 g fillet/day for 8 weeks, 3 days per week)
Trial: 34684525
Drug: Yellowstripe scad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellowstripe scad (385 g whole fish/day for 8 weeks, 3 days per week)
Trial: 33263234
Drug: CEF (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (125 mg/quarter intramammary)
Trial: 33764324
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone 100 mg/d for 8 weeks
Trial: 32464280
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily for 3 weeks on/1 week off
Trial: 39468623
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy
Trial: 36261594
Drug: Structured Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Water Dance Intervention (SWAN), administered for 40 minutes once a week during a 12-week period.
Trial: 33839923
Drug: Anemia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia group (hemoglobin < 12 g/dL for women and < 13 g/dL for men)
Trial: 32618212
Drug: Group Music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Music (GM) - 30-minute musical intervention before chemotherapy
Trial: 34560835
Drug: Remifentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil plasma target concentration 0 ng/ml (Group R0)
Trial: 34560835
Drug: Remifentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil plasma target concentration 2 ng/ml (Group R2)
Trial: 35131440
Drug: Sham CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham CPAP treatment
Trial: 35020052
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 500 mg daily for 12 months
Trial: 35416981
Drug: Exendin-(9-39) 0.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin-(9-39) 0.44 mg/kg
Trial: 35416981
Drug: Exendin-(9-39) 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin-(9-39) 0.6 mg/kg
Trial: 35416981
Drug: Exendin-(9-39) 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin-(9-39) 0.6 mg/kg during MMTT
Trial: 35416981
Drug: Exendin-(9-39) 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin-(9-39) 0.6 mg/kg during OPTT
Trial: 32847444
Drug: Changweishu combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changweishu combined with routine Western medicine treatment
Trial: 32847444
Drug: Routine Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Western medicine treatments (meropenem, noradrenaline, glutamine glue, Bifidobacterium lactis triple‐strain tablet)
Trial: 35760724
Drug: Stratified exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified exercise therapy (including dietary intervention for obesity subgroup)
Trial: 35760724
Drug: Usual exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual exercise therapy (control)
Trial: 35466705
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to Occupational Performance intervention (one hour weekly for 10 weeks)
Trial: 32475989
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine infusion
Trial: 35148626
Drug: Sterile polyacrylate
RxNorm normalized name: polyacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile polyacrylate wound pad with activated carbon cloth treatment